首页> 外文OA文献 >PDB8 CLINICAL BENEFITS OF PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) AND EZETIMIBE IN STATIN-TREATED TYPE-2 DIABETES PATIENTS FAILING TO REACH TARGET CHOLESTEROL LEVELS

【2h】

PDB8 CLINICAL BENEFITS OF PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) AND EZETIMIBE IN STATIN-TREATED TYPE-2 DIABETES PATIENTS FAILING TO REACH TARGET CHOLESTEROL LEVELS

机译：他汀类药物治疗的2型糖尿病患者达到目标胆固醇水平的增强释放烟酸（NIASPAN®）和依泽替尼的PDB8临床益处

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Liens D; Roze S; Valentine WJ; Minshall ME; Palmer AJ; Renaudin C;
展开▼
作者单位

展开▼
年度 2005
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Clinical Experience With Prolonged-Release Nicotinic Acid in Statin-Treated Patients Managed in the Usual-Care Setting in Austria: An Analysis from Niaspan?-Induced HDL-Elevation for Optimizing Risk Control (NEMO) Study [J] . Drexel H, Hostalek U, Kastelein J, Journal of Clinical and Basic Cardiology (Print): an independent international scientific journal . 2008,第1期

机译：在奥地利通常护理环境中接受标准治疗的患者中长期释放烟酸的临床经验：一项由Niaspan？诱导的HDL升高以优化风险控制（NEMO）研究的分析
2. Cost-effectiveness of adding prolonged-release nicotinic acid in statin-treated patients who achieve LDL cholesterol goals but remain at risk due to low HDL cholesterol: A UK-based economic evaluation [J] . Roze S, Wierzbicki A.S, Liens D, The British journal of cardiology . 2006,第6期

机译：基于他汀类药物治疗的患者达到LDL胆固醇目标但由于低HDL胆固醇而仍然处于危险之中时，添加烟碱延长释放的成本效益：基于英国的经济评估
3. Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan). [J] . Vogt A, Kassner U, Hostalek U, International journal of clinical practice . 2007,第11期

机译：纠正低HDL胆固醇以降低心血管疾病的风险：与长期使用烟酸（Niaspan）的治疗性使用有关的实际考虑。
4. Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial [O] . Hiroyuki Hirai, Moritake Higa, Takeshi Morimoto, 2020

机译：Anagliptin和Sitagliptin对标准或强力他汀治疗的2型糖尿病患者脂蛋白亚类的不同作用：REASON的亚分析（Anagliptin与Sitagliptin的糖尿病低密度脂蛋白胆固醇的随机评价）试验
5. PDB17 ECONOMIC ASSESSMENT OF ADD-ON THERAPY WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) IN STATIN-TREATED PATIENTS WITH DYSLIPIDEMIA AND TYPE-2 DIABETES IN GERMANY AND SWEDEN [O] . Berger W, Roze S, Palmer AJ, 2005

机译：PDB17在德国和瑞典对他汀类药物治疗的运动障碍和2型糖尿病患者进行长期释放烟酸（NIASPAN®）补充治疗的经济评估

PDB8 CLINICAL BENEFITS OF PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) AND EZETIMIBE IN STATIN-TREATED TYPE-2 DIABETES PATIENTS FAILING TO REACH TARGET CHOLESTEROL LEVELS

著录项

相似文献

相关主题

期刊订阅